Medivir to present at the Redeye Technology & Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will participate at the Redeye Technology & Life Science Day, tomorrow, December 3, 2024.

CEO Jens Lindberg will participate in an In Focus interview at 10.40 CET, led by Redeye analyst Richard Ramanius. The interview will focus on the recently presented data at the ESMO conference and how they strengthen the ambition to make fostrox + Lenvima® the first, approved treatment option in second-line HCC.
 
 
The presentation is live broadcasted and can be followed at the event page;
https://www.redeye.se/events/1038747/redeye-technology-life-science-day
The presentation will be available on Medivir’s website after the meeting.

Datum 2024-12-02, kl 10:00
Källa MFN
Bifogade filer
Ungdomsdeal - 200 kr ! Just nu får alla nya kunder mellan 18 och 25 år 200 kr gratis när man skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra läge att testa Nordnet!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet